publication date: Oct. 30, 2015

A Third of Hospitals Will Drop Out of 340B if HRSA Enacts New Guidance, Survey Finds 

 

Hospitals serving large populations of low-income patients stand to lose up to seven figures a year in drug discounts if proposed regulatory changes to the 340B program are enacted, the program’s supporters say.

The Health Resources and Services Administration issued a sweeping guidance that would provide stricter definitions for which patients and entities should be covered (The Cancer Letter, Sept. 11).

The draft guidance, called the 340B Program Omnibus Guidance, was issued Aug. 28. Its public comment period for the long-awaited “mega-guidance” ended Oct. 27 (The Cancer Letter, Oct. 16).

HRSA’s new guidelines for the 340B Drug Discount Program would have a devastating impact on hospitals’ ability to provide uncompensated care to needy patients, said 340B Health, a Washington, D.C. association.

In a recent survey of its members, the group found that—if the guidance is finalized—about a third of hospitals would be forced to drop out of the discount program. Half of the hospitals surveyed said the proposed rules were “highly problematic” to their patient care mission.

“As we prepared our comments, we were struck by how many hospitals contacted us to raise serious concerns about the proposal,” Ted Slafsky, president and CEO of 340B Health, said Oct. 28. “The bottom line: The number of hospitals that would be hurt by the proposed mega-guidance is staggering. We hope HRSA hears our concerns and significantly modifies the final … Continue reading 41-40 A Third of Hospitals Will Drop Out of 340B if HRSA Enacts New Guidance, Survey Finds

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.